Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 10, Number 12—December 2004

Genome Sequence and Attenuating Mutations in West Nile Virus Isolate from Mexico

David W.C. Beasley*Comments to Author , C. Todd Davis*, Jose Estrada-Franco*, Roberto Navarro-Lopez†, Arturo Campomanes-Cortes†, Robert B. Tesh*, Nikos Vasilakis*, and Alan D.T. Barrett*
Author affiliations: *University of Texas Medical Branch, Galveston, Texas, USA; †Comision Mexico-Estados Unidos para la Prevencion de la Fiebre Aftosa y Otras Enfermedades Exoticas de los Animales, Mexico City, Mexico

Main Article

Table 2

Neuroinvasiveness and neurovirulence of TM-171 Mex03 parental isolate and plaque-purified variants after injection into 3- to 4-week-old female NIH Swiss micea

Virus E154-156 sequence i.p. LD50 (PFU) i.p. AST ± SD (d)b i.c. LD50 (PFU) i.c. AST ± SD (d)b
TM171-03 NYP/S 1.3 7.9 ± 0.7 0.8 6.2 ± 1.8
TM171-03-pp1 NYP >1000 NA 32 6.0 ± 0.9
TM171-03-pp2 NYP >1000 NA 25 6.7 ± 1.7
TM171-03-pp5 NYS 2.0 9.0 ± 1.4 2.0 7.4 ± 1.2
TM171-03-pp6 NYS 2.0 8.5 ± 1.7 1.3 7.4 ± 0.9

aNIH, National Institutes of Health; AST, average survival time; i.p., intraperitoneal; i.c., intracranial; LD50, 50% lethal dose; SD, standard deviation; NA, not applicable.
bAverage survival time ± SD was calculated for all animals that died following inoculation with 1,000 - 0.1 PFU doses of indicated virus.

Main Article

Page created: April 14, 2011
Page updated: April 14, 2011
Page reviewed: April 14, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.